Drug Trial Radar · NCT06438263
A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Aug 6, 2024
Primary completion
May 3, 2025
Study completion Jul 2, 2025
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- May 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.
Conditions
- Atopic Dermatitis
Interventions
RocatinlimabDrug
Vial supplied as a single-use preservative free solution for SC injection.
RocatinlimabDrug
Autoinjector for SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of RocatinlimabTime frame: Up to approximately 112 days
- Area Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of RocatinlimabTime frame: Up to approximately 112 days
- AUC From Time Zero to Infinity (AUCinf) of RocatinlimabTime frame: Up to approximately 112 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida
Fortrea Clinical Research Unit - Dallas
Dallas, Texas
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.